The surprise approval of iloperidone ( Fanapt ) earned back in May by Vanda Pharmaceuticals had a lot of people (OK maybe just us?) scratch...

We got those kozmik post-Pharmaceutical Strategic Alliances blues again, mama, moving from our jam-packed coffee-and-schmooze-fueled confab ...

This morning we learned that former AstraZeneca CFO and current Goldman Sachs partner Jon Symonds (right) is leaving that bank to join Novar...

The recently and some-say miraculously approved iloperidone ( Fanapt ) from Vanda Pharmaceuticals is certainly a rare bird. (Full coverage ...

Much ink has been spilt this week here and elsewhere about what the election of Barack Obama as 44th POTUS and the continued ascendence of t...

In our last out-partnering post , we suggested the possibility that out-partnering could spur a wholesale change in business model, using Pf...

Lots of interest in out-partnering these days from Big Pharma – out-licensing, spin-offs, project financing ( see in particular this IN VIVO...

When Michael Gilman, PhD, left his post as EVP of research at Biogen Idec Inc. in late 2005, his goal was to start afresh. He quickly hooked...

You would have thought Big Pharma's increasing willingness to outlicense would be good news for the industry. VCs love getting their han...

Remember Biovitrum? That Swedish biotech spun out of Pharmacia in 2001, hailed as a key driver of Europe's burgeoning biotech sector? W...

Just when we thought that drug companies had given up on some of their more blatant life-cycle management tricks, snubbed by stingy payors w...